Armistice Capital LLC Has $22.91 Million Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Posted by Brian Himes on Jun 18th, 2026

Armistice Capital LLC grew its position in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Free Report) by 8.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,236,000 shares of the company’s stock after purchasing an additional 258,000 shares during the period. Armistice Capital LLC’s holdings in Bicycle Therapeutics were worth $22,911,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of BCYC. GSK plc acquired a new position in shares of Bicycle Therapeutics during the 4th quarter valued at about $10,829,000. Schroder Investment Management Group acquired a new position in shares of Bicycle Therapeutics during the 4th quarter valued at about $3,976,000. Woodline Partners LP acquired a new position in shares of Bicycle Therapeutics during the 1st quarter valued at about $3,088,000. Birchview Capital LP increased its holdings in shares of Bicycle Therapeutics by 200.5% during the 4th quarter. Birchview Capital LP now owns 462,700 shares of the company’s stock valued at $3,276,000 after acquiring an additional 308,700 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Bicycle Therapeutics by 156.5% during the 1st quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock valued at $3,850,000 after acquiring an additional 276,671 shares during the last quarter. 86.15% of the stock is owned by institutional investors and hedge funds.

Bicycle Therapeutics Stock Up 0.5%

Shares of NASDAQ:BCYC opened at $4.04 on Thursday. The business has a 50 day moving average price of $4.64 and a 200 day moving average price of $5.56. Bicycle Therapeutics PLC Sponsored ADR has a twelve month low of $3.95 and a twelve month high of $9.18. The company has a market cap of $282.03 million, a price-to-earnings ratio of -1.28 and a beta of 1.54.

Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.25). Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%.The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $7.50 million. Analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -2.01 EPS for the current year.

Insider Activity at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,967 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $4.91, for a total value of $29,297.97. Following the completion of the sale, the chief executive officer owned 613,029 shares in the company, valued at approximately $3,009,972.39. This trade represents a 0.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 9,992 shares of company stock valued at $49,363. 22.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Citizens Jmp lowered their price objective on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a report on Wednesday, March 18th. Needham & Company LLC lowered their price objective on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Truist Financial set a $8.00 price objective on Bicycle Therapeutics in a report on Tuesday, March 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, April 10th. Finally, Citigroup restated a “market outperform” rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $14.00.

Read Our Latest Stock Analysis on Bicycle Therapeutics

Bicycle Therapeutics Profile

(Free Report)

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.